onclive·May 5·1 min readsaveHS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI ResistanceMay 5, 2026·read at onclive ↗Phase 1 data show HS-10504 yields encouraging responses and manageable safety in EGFR C797S–mutant NSCLC post TKI therapy.sourceReporting by onclive.read at onclive ↗sharecopy linkx / twitterlinkedinmore…
comments(0)
5-min edit window · permanent after that